ALPMY News and Press, Astellas Pharma Inc. ADR From 12/24/20

FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline consists of two late-stage/commercialized therapeutics and one medical product all with seve...

Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy PR Newswire TOKYO , Dec...

KaliVir Immunotherapeutics has entered into a worldwide licensing agreement for the research, development, and commercialization of VET2-L2 with Astellas Pharma (ALPMY)Under the terms of the agreement, Astellas will pay to KaliVir up to $56M in the form of an upfront payment and other payment...

KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus PITTSBURGH and TOKYO , Dec. 7, 2020 /PRNewswire/ -- KaliVir Immunotherapeutics LLC  (CEO: Helena C...

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CK...

Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 American Society of Hematology Annual Meeting Includes five oral presentations that collectively explore the use of gilteritinib across the FLT3mut+ AML care continuum P...

XTANDI® (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer Enzalutamide is now NMPA-approved for both non-metastatic and metastatic castration-resistant prostate cancer PR Newswire TOKYO, Nov....

Astellas Pharma Inc. (ALPMY) Q2 2020 Earnings Conference Call October 30, 2020 01:00 AM ET Company Participants Kenji Yasukawa - President & Chief Executive Officer Naoki Okamura - Representative Director & Executive Vice President Yukio Matsui - Chief Commercial Officer Mike Kitagawa...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q2 earnings call. For further details see: Astellas Pharma Inc. 2020 Q2 - Results - Earnings Call Presentation

Astellas Pharma ADR (ALPMY): 1H Non-GAAP EPS of ¥57.15; GAAP EPS of ¥39.19.Revenue of ¥615.48B (-5.4% Y/Y)Press Release For further details see: Astellas Pharma ADR reports 1H results